Samsung Bioepis (CEO Hansung Ko) announced today that the company had presented the follow-up results from its Phase III clinical trial on SB15 (Korean brand name: Afilivu/Eylea biosimilar/Aflibercept) at the Annual Asia-Pacific Academy of Ophthalmology (APAO) Congress that was held in Indonesia from the 22nd to the 25th this month,

SB15 is a biosimilar of Eylea, the eye diseases treatment for diseases such as macular degeneration that was developed by the U.S. company Regeneron in the U.S. It works by binding to the vascular endothelial growth factor (VEGF) and inhibiting the formation of new blood vessels.

Macular degeneration is an ocular disease caused by aging and inflamm